HISTONE DEACETYLASE INHIBITOR
Zolinza is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat skin symptoms in people with cutaneous T-cell lymphoma (CTCL). Zolinza is indicated for use in patients when CTCL has persisted, progressed, or recurred despite two other systemic therapies. Zolinza is also referred to by its drug name, vorinostat.
Zolinza is an anticancer drug and is a member of a class of drugs called histone deacetylase inhibitors. Zolinza is believed to work by slowing the growth of cancer cells and then killing them.
How do I take it?
Zolinza is taken orally once daily with food.
Zolinza comes in capsule form.
The FDA-approved label for Zolinza lists common side effects including fatigue, changes to the sense of taste, nausea, diarrhea, low blood cell counts, elevated blood sugar, and loss of appetite.
Rare but serious side effects listed for Zolinza include dangerously low blood cell counts, severe gastrointestinal symptoms, fetal harm in pregnant women, gastrointestinal bleeding, and potentially life-threatening blood clots.
For more details about this treatment, visit:
Zolinza Highlights of Prescribing Information — Merck
Treatment for Indolent NHL Subtypes — Leukemia & Lymphoma Society